(αS)-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic Acid; (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic Acid; (S)-Carbidopa; 1-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic Acid; Carbidopa; HMD; Hydrazino-α-methyldopa; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic Acid; L-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic Acid; L-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic Acid; L-α-Methyldopahydrazine; Lodosin; Lodosyn; MK 486; N-Aminomethyldopa; α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic Acid; α-Methyldopahydrazine;

(S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.